Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902193 | 0.88 | PDE4B (0.44) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL31391778 | 0.86 | HPGD (0.44) | NR1H2PDE4BUSP2SMN1; SMN2MEN1 | |
| SCHEMBL14800638 | 0.86 | NR1H2 (0.55) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL14805513 | 0.86 | NR1H2 (0.55) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL14801588 | 0.86 | NR1H2 (0.55) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL13098438 | 0.85 | NR1H2 (0.53) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL9972997 | 0.85 | NR1H2 (0.53) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL19083300 | 0.85 | NR1H2 (0.53) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL14805523 | 0.84 | NR1H2 (0.47) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT | |
| SCHEMBL24126972 | 0.84 | NR1H2 (0.47) | NR1H2PDE4BUSP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137053-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197374-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2025-06-19 | — | — | US | disclosed |
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | NR1H2 1338/4885PDE4B 3125/4885USP2 3856/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | NR1H2 2517/4885PDE4B 3995/4885USP2 1965/4885 |
| US-20250197374-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | WEE1, WEE2, PPME1 | NR1H2 3366/4885PDE4B 3170/4885USP2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.